Tomoyuki Mizuno1, Tsuyoshi Fukuda1,2, Uwe Christians3, John P Perentesis4,2, Maryam Fouladi4,2, Alexander A Vinks1,2. 1. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 2. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA. 3. iC42 Clinical Research and Development, University of Colorado, Aurora, Colorado, USA. 4. Division of Oncology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Abstract
AIMS: Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR). Pharmacokinetic (PK) characterization of temsirolimus in children is limited and there is no paediatric temsirolimus population PK model available. The objective of this study was to simultaneously characterize the PK of temsirolimus and its metabolite sirolimus in paediatric patients with recurrent solid or central nervous system tumours and to develop a population PK model. METHODS: The PK data for temsirolimus and sirolimus were collected as a part of a Children's Oncology Group phase I clinical trial in paediatric patients with recurrent solid tumours. Serial blood concentrations obtained from 19 patients participating in the PK portion of the study were used for the analysis. Population PK analysis was performed by nonlinear mixed effect modelling using NONMEM. RESULTS: A three-compartment model with zero-order infusion was found to best describe temsirolimus PK. Allometrically scaled body weight was included in the model to account for body size differences. Temsirolimus dose was identified as a significant covariate on clearance. A sirolimus metabolite formation model was developed and integrated with the temsirolimus model. A two-compartment structure model adequately described the sirolimus data. CONCLUSION: This study is the first to describe a population PK model of temsirolimus combined with sirolimus formation and disposition in paediatric patients. The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children.
AIMS: Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR). Pharmacokinetic (PK) characterization of temsirolimus in children is limited and there is no paediatric temsirolimus population PK model available. The objective of this study was to simultaneously characterize the PK of temsirolimus and its metabolite sirolimus in paediatric patients with recurrent solid or central nervous system tumours and to develop a population PK model. METHODS: The PK data for temsirolimus and sirolimus were collected as a part of a Children's Oncology Group phase I clinical trial in paediatric patients with recurrent solid tumours. Serial blood concentrations obtained from 19 patients participating in the PK portion of the study were used for the analysis. Population PK analysis was performed by nonlinear mixed effect modelling using NONMEM. RESULTS: A three-compartment model with zero-order infusion was found to best describe temsirolimus PK. Allometrically scaled body weight was included in the model to account for body size differences. Temsirolimus dose was identified as a significant covariate on clearance. A sirolimus metabolite formation model was developed and integrated with the temsirolimus model. A two-compartment structure model adequately described the sirolimus data. CONCLUSION: This study is the first to describe a population PK model of temsirolimus combined with sirolimus formation and disposition in paediatric patients. The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children.
Authors: Scott Okuno; Howard Bailey; Michelle R Mahoney; Douglas Adkins; William Maples; Tom Fitch; David Ettinger; Charles Erlichman; Jann N Sarkaria Journal: Cancer Date: 2011-02-01 Impact factor: 6.860
Authors: Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544
Authors: Manuel Hidalgo; Jan C Buckner; Charles Erlichman; Marilyn S Pollack; Joseph P Boni; Gary Dukart; Bonnie Marshall; Lisa Speicher; Laurence Moore; Eric K Rowinsky Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: Sonali M Smith; Koen van Besien; Theodore Karrison; Janet Dancey; Peter McLaughlin; Anas Younes; Scott Smith; Patrick Stiff; Eric Lester; Sanjiv Modi; L Austin Doyle; Everett E Vokes; Barbara Pro Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Eudocia Q Lee; John Kuhn; Kathleen R Lamborn; Lauren Abrey; Lisa M DeAngelis; Frank Lieberman; H Ian Robins; Susan M Chang; W K Alfred Yung; Jan Drappatz; Minesh P Mehta; Victor A Levin; Kenneth Aldape; Janet E Dancey; John J Wright; Michael D Prados; Timothy F Cloughesy; Mark R Gilbert; Patrick Y Wen Journal: Neuro Oncol Date: 2012-10-24 Impact factor: 12.300
Authors: Edwin A Alvarez; William E Brady; Joan L Walker; Jacob Rotmensch; Xun C Zhou; James E Kendrick; S Diane Yamada; Jeanne M Schilder; David E Cohn; Charles R Harrison; Kathleen N Moore; Carol Aghajanian Journal: Gynecol Oncol Date: 2012-12-20 Impact factor: 5.482
Authors: Hajar Alammar; Rayan Nassani; Mana M Alshehri; Alaa A Aljohani; Bahauddeen M Alrfaei Journal: Int J Mol Sci Date: 2021-12-31 Impact factor: 5.923